These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 30037618)

  • 1. Plerixafor and related macrocyclic amines are potential drug candidates in treatment of malaria by "filling the flap" region of plasmepsin enzymes.
    Abiri A
    Med Hypotheses; 2018 Sep; 118():68-73. PubMed ID: 30037618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Picomolar Inhibition of Plasmepsin V, an Essential Malaria Protease, Achieved Exploiting the Prime Region.
    Gambini L; Rizzi L; Pedretti A; Taglialatela-Scafati O; Carucci M; Pancotti A; Galli C; Read M; Giurisato E; Romeo S; Russo I
    PLoS One; 2015; 10(11):e0142509. PubMed ID: 26566224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimalarial evaluation of copper(II) nanohybrid solids: inhibition of plasmepsin II, a hemoglobin-degrading malarial aspartic protease from Plasmodium falciparum.
    Mohapatra SC; Tiwari HK; Singla M; Rathi B; Sharma A; Mahiya K; Kumar M; Sinha S; Chauhan SS
    J Biol Inorg Chem; 2010 Mar; 15(3):373-85. PubMed ID: 19946719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dietary flavonoids fisetin and myricetin: dual inhibitors of Plasmodium falciparum falcipain-2 and plasmepsin II.
    Jin H; Xu Z; Cui K; Zhang T; Lu W; Huang J
    Fitoterapia; 2014 Apr; 94():55-61. PubMed ID: 24468190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. QSAR, docking and ADMET studies of artemisinin derivatives for antimalarial activity targeting plasmepsin II, a hemoglobin-degrading enzyme from P. falciparum.
    Qidwai T; Yadav DK; Khan F; Dhawan S; Bhakuni RS
    Curr Pharm Des; 2012; 18(37):6133-54. PubMed ID: 22670592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimalarial synergy of cysteine and aspartic protease inhibitors.
    Semenov A; Olson JE; Rosenthal PJ
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2254-8. PubMed ID: 9736544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Click Inspired Synthesis of Novel Cinchonidine Glycoconjugates as Promising Plasmepsin Inhibitors.
    Mishra N; Agrahari AK; Bose P; Singh SK; Singh AS; Tiwari VK
    Sci Rep; 2020 Feb; 10(1):3586. PubMed ID: 32108142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New paradigm of an old target: an update on structural biology and current progress in drug design towards plasmepsin II.
    Dan N; Bhakat S
    Eur J Med Chem; 2015 May; 95():324-48. PubMed ID: 25827401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring the flap pocket of the antimalarial target plasmepsin II: the "55 % rule" applied to enzymes.
    Zürcher M; Gottschalk T; Meyer S; Bur D; Diederich F
    ChemMedChem; 2008 Feb; 3(2):237-40. PubMed ID: 17918177
    [No Abstract]   [Full Text] [Related]  

  • 10. Exploring Aspartic Protease Inhibitor Binding to Design Selective Antimalarials.
    Bobrovs R; Basens EE; Drunka L; Kanepe I; Matisone S; Velins KK; Andrianov V; Leitis G; Zelencova-Gopejenko D; Rasina D; Jirgensons A; Jaudzems K
    J Chem Inf Model; 2022 Jul; 62(13):3263-3273. PubMed ID: 35712895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimalarial Phytochemicals Identification from
    Shah AP; Parmar GR; Sailor GU; Seth AK
    Folia Med (Plovdiv); 2019 Dec; 61(4):584-593. PubMed ID: 32337872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and characterization of allophenylnorstatine-based inhibitors of plasmepsin II, an antimalarial target.
    Nezami A; Luque I; Kimura T; Kiso Y; Freire E
    Biochemistry; 2002 Feb; 41(7):2273-80. PubMed ID: 11841219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of new plasmepsin inhibitors: a virtual high throughput screening approach on the EGEE grid.
    Kasam V; Zimmermann M; Maass A; Schwichtenberg H; Wolf A; Jacq N; Breton V; Hofmann-Apitius M
    J Chem Inf Model; 2007; 47(5):1818-28. PubMed ID: 17727268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structures of plasmepsin II from Plasmodium falciparum in complex with two hydroxyethylamine-based inhibitors.
    Recacha R; Leitans J; Akopjana I; Aprupe L; Trapencieris P; Jaudzems K; Jirgensons A; Tars K
    Acta Crystallogr F Struct Biol Commun; 2015 Dec; 71(Pt 12):1531-9. PubMed ID: 26625296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New inhibitors of the malaria aspartyl proteases plasmepsin I and II.
    Dahlgren A; Kvarnström I; Vrang L; Hamelink E; Hallberg A; Rosenquist A; Samuelsson B
    Bioorg Med Chem; 2003 Aug; 11(16):3423-37. PubMed ID: 12878137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitors of the Plasmodium falciparum parasite aspartic protease plasmepsin II as potential antimalarial agents.
    Boss C; Richard-Bildstein S; Weller T; Fischli W; Meyer S; Binkert C
    Curr Med Chem; 2003 Jun; 10(11):883-907. PubMed ID: 12678679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insight into selectivity of peptidomimetic inhibitors with modified statine core for plasmepsin II of Plasmodium falciparum over human cathepsin D.
    Dali B; Keita M; Megnassan E; Frecer V; Miertus S
    Chem Biol Drug Des; 2012 Apr; 79(4):411-30. PubMed ID: 22129033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasmepsin Inhibitors in Antimalarial Drug Discovery: Medicinal Chemistry and Target Validation (2000 to Present).
    Cheuka PM; Dziwornu G; Okombo J; Chibale K
    J Med Chem; 2020 May; 63(9):4445-4467. PubMed ID: 31913032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of potent inhibitors of Plasmodium falciparum plasmepsin II from an encoded statine combinatorial library.
    Carroll CD; Patel H; Johnson TO; Guo T; Orlowski M; He ZM; Cavallaro CL; Guo J; Oksman A; Gluzman IY; Connelly J; Chelsky D; Goldberg DE; Dolle RE
    Bioorg Med Chem Lett; 1998 Sep; 8(17):2315-20. PubMed ID: 9873534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the Plasmodium falciparum plasmepsin V by ligand-based virtual screening.
    Meissner KA; Kronenberger T; Maltarollo VG; Trossini GHG; Wrenger C
    Chem Biol Drug Des; 2019 Mar; 93(3):300-312. PubMed ID: 30320974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.